Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Aug 28, 2026 · 10-Q · 59 days after period end · 0001731122-26-001167
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | $7.82M | -$13.24M | -$12.21M | -$11.28M |
| EPS Diluted | $0.08 | -$0.16 | -$0.14 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 28, 2026 · 59 d after period end
